Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354516 · ClinicalTrials.gov registry record · Phase 2
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study of OHT - Ocular Hypertension and OAG - Open-Angle Glaucoma, sponsored by Qlaris Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT07354516: Recruiting Phase 2 study of OHT - Ocular Hypertension and OAG - Open-Angle Glaucoma, sponsored by Qlaris Bio.
NCT07354516 is a Phase 2 study of OHT - Ocular Hypertension and OAG - Open-Angle Glaucoma that is actively recruiting participants, run by Qlaris Bio. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07354516, a Phase 2 study of OHT - Ocular Hypertension and OAG - Open-Angle Glaucoma, is actively recruiting participants, sponsored by Qlaris Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Primary Outcome
Change from baseline in IOP, lowering of IOP compared to baseline is desirable outcome.
Conditions Studied
Interventions
- COMBINATION_PRODUCT QLS-111-FDC
- DRUG Latanoprost (0.005%)
Study Locations (1)
Florida
- Shettle Eye Research - Largo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2026-07-15 |
| Phase | Phase 2 |
What NCT07354516 shows while recruiting
NCT07354516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 2 conditions, with OHT - Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which QLS-111-FDC is the first listed.
NCT07354516 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07354516 about?
NCT07354516 is a clinical study titled "Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension". Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
What is the current status of trial NCT07354516?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2026-03-18. Estimated completion is 2026-07-15.
What conditions does trial NCT07354516 study?
This clinical trial studies the following conditions: OHT - Ocular Hypertension, OAG - Open-Angle Glaucoma.
What interventions are being tested in trial NCT07354516?
The interventions under investigation include: QLS-111-FDC (COMBINATION_PRODUCT), Latanoprost (0.005%) (DRUG).
Who is sponsoring clinical trial NCT07354516?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07354516 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OHT - Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07354516's enrollment target sits among peer trials
36 1496th of 2000 higher than 478 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI